Financial Tear Sheet

Corporate Profile

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune/Roche) having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.

Primary IR Contact
Michael Carruthers
Chief Financial Officer
Phone: (303) 381-6663
E-mail: Michael.Carruthers@arraybiopharma.com

Tricia Haugeto
Senior Manager, Communications
Phone: (303) 386-1193
E-mail: Tricia.Haugeto@arraybiopharma.com

Stock Performance
ARRY (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.66
Change (%) Stock is Down 0.14 (2.41%)
Volume1,704,536
52 Week Low$3.00
Market Cap$660,952,160
Rolling EPS-0.51
PE RatioN/A
Shares Outstanding116,776,000
Data as of 05/23/13 4:00 p.m. ET
Stock chart for: 03NA000000ARRY
Recent Headlines & Events
05/15/13 - 8:00 a.m.
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
05/08/13 - 8:00 a.m.
Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
05/06/13 - 4:07 p.m.
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 1.5

Buy
SellStrong Buy
EPS Trend
  Current30 Days Ago90 Days Ago
QTRJun 13-0.13-0.17-0.17
QTRSep 13-0.16-0.16-0.16
QTRDec 13-0.15-0.16-0.16
QTRMar 14-0.15-0.15-0.15
FYJun 13-0.55-0.55-0.55
FYJun 14-0.46-0.46-0.46
SEC Filings
Filing DateForm
05/07/134 XBRL SEC Filing Unavailable
05/07/1310-Q Download XBRL Content
05/06/138-K XBRL SEC Filing Unavailable
05/06/138-K XBRL SEC Filing Unavailable
Corporate Governance
Ron SquarerChief Executive Officer
R. Michael CarruthersChief Financial Officer
Gary M. Clark, Ph.D.Vice President, Biostatistics & Data Management
Howard Holden, Ph.D.Vice President, Regulatory Affairs & Quality Assurance
Kevin  Koch, Ph.D.President & Chief Scientific Officer
Patrice Lee, Ph.D.Vice President, Pharmacology & Toxicology
John R. MooreVice President & General Counsel
Michael N. Needle, M.D.Chief Medical Officer
Andrew RobbinsSenior Vice President, Commercial Operations
David L. Snitman, Ph.D.Chief Operating Officer & Vice President, Business Development
James D. Winkler, Ph.D.Vice President, Discovery & Translational Biology
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution160489.5285.199,315,279
Mutual Fund13695.3517.520,413,214
Insider *19124.7218.221,283,205
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
Biotechnology Value Fund, Inc.11,431,8589.8003/31/13
Deerfield Management Company, L.P.11,244,7009.6003/31/13
BlackRock Institutional Trust Company, N.A.8,472,3067.31,815,97503/31/13
OrbiMed Advisors, LLC4,792,2004.1462,10003/31/13
Redmile Group, LLC4,724,0204.1347,50003/31/13
QVT Financial LP4,300,0003.7003/31/13
The Vanguard Group, Inc.3,741,2013.2499,30603/31/13
Ratcliffe (Liam T)3,239,2002.83,239,20008/27/12
Kopp Investment Advisors, LLC3,214,5342.85,02503/31/13
State Street Global Advisors (US)3,168,6122.7-420,97303/31/13

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Minimum 20 minutes delayed